5.71
price down icon4.19%   -0.25
after-market Dopo l'orario di chiusura: 5.70 -0.010 -0.18%
loading
Precedente Chiudi:
$5.96
Aprire:
$5.92
Volume 24 ore:
479.46K
Relative Volume:
1.08
Capitalizzazione di mercato:
$351.22M
Reddito:
-
Utile/perdita netta:
$-130.41M
Rapporto P/E:
-2.5491
EPS:
-2.24
Flusso di cassa netto:
$-67.76M
1 W Prestazione:
-3.22%
1M Prestazione:
+20.46%
6M Prestazione:
+3.44%
1 anno Prestazione:
+29.77%
Intervallo 1D:
Value
$5.64
$5.92
Intervallo di 1 settimana:
Value
$5.4529
$6.25
Portata 52W:
Value
$3.5001
$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name
Nome
Monte Rosa Therapeutics Inc
Name
Telefono
617-949-2643
Name
Indirizzo
321 HARRISON AVENUE, BOSTON
Name
Dipendente
134
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
GLUE's Discussions on Twitter

Confronta GLUE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
GLUE
Monte Rosa Therapeutics Inc
5.71 366.60M 0 -130.41M -67.76M -2.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-19 Downgrade Wells Fargo Overweight → Equal Weight
2024-02-15 Iniziato Wedbush Outperform
2023-01-03 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-10-13 Iniziato UBS Buy
2022-08-15 Iniziato Jefferies Buy
2022-04-28 Iniziato Credit Suisse Neutral
2022-02-10 Iniziato Wells Fargo Equal Weight
2021-10-14 Iniziato SVB Leerink Mkt Perform
Mostra tutto

Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie

pulisher
Jul 24, 2025

What analysts say about Monte Rosa Therapeutics Inc. stockOverwhelming profit margins - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan

Jul 21, 2025
pulisher
Jul 18, 2025

Monte Rosa (GLUE) Soars 13.58% in Three Days, Hits 2025 High - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st

Jul 18, 2025
pulisher
Jul 17, 2025

Monte Rosa Therapeutics Inc (GLUE) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Jul 17, 2025
pulisher
Jul 16, 2025

How Monte Rosa Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Monte Rosa Therapeutics Inc. stock price move sharplyFree Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention2x 3x 5x Pick Alert - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

With surface mimicry, molecular glues shed hairpin need - BioWorld MedTech

Jul 15, 2025
pulisher
Jul 09, 2025

Monte Rosa Therapeutics (GLUE) Soars 4.55% on Clinical Trial Progress - AInvest

Jul 09, 2025
pulisher
Jul 04, 2025

Monte Rosa Therapeutics (GLUE): Pioneering the Future of Drug Discovery with Molecular Glue Degraders - AInvest

Jul 04, 2025
pulisher
Jul 03, 2025

Monte Rosa Therapeutics Announces Publication of Landmark Research on Molecular Glue Degraders in Science - Nasdaq

Jul 03, 2025
pulisher
Jul 03, 2025

Monte Rosa Announces Publication in Science of Key Insights - GlobeNewswire

Jul 03, 2025
pulisher
Jul 03, 2025

Monte Rosa Announces Publication in Science of Key Insights That Enable Next Generation Molecular Glue Degrader Medicines - MarketScreener

Jul 03, 2025
pulisher
Jul 03, 2025

Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition - Science | AAAS

Jul 03, 2025

Monte Rosa Therapeutics Inc Azioni (GLUE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):